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In-Frame Mutations in Exon 1 of SKI
Cause Dominant Shprintzen-Goldberg Syndrome
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Clarisse Baumann,18 Maja Di Rocco,19 Jaime Sanchez Del Pozo,20 Fre´de´ric Huet,1 Guillaume Jondeau,21
Gwenae¨lle Collod-Beroud,22 Christophe Beroud,22,23 Jeanne Amiel,23 Vale´rie Cormier-Daire,24
Jean-Baptiste Rivie`re,1,12 Catherine Boileau,25 Anne De Paepe,6 and Laurence Faivre1,2,*
Shprintzen-Goldberg syndrome (SGS) is characterized by severe marfanoid habitus, intellectual disability, camptodactyly, typical facial
dysmorphism, and craniosynostosis. Using family-based exome sequencing, we identified a dominantly inherited heterozygous in-
frame deletion in exon 1 of SKI. Direct sequencing of SKI further identified one overlapping heterozygous in-frame deletion and ten
heterozygous missense mutations affecting recurrent residues in 18 of the 19 individuals screened for SGS; these individuals included
one family affected by somatic mosaicism. All mutations were located in a restricted area of exon 1, within the R-SMAD binding domain
of SKI. No mutation was found in a cohort of 11 individuals with other marfanoid-craniosynostosis phenotypes. The interaction
between SKI and Smad2/3 and Smad 4 regulates TGF-b signaling, and the pattern of anomalies in Ski-deficient mice corresponds to
the clinical manifestations of SGS. These findings define SGS as a member of the family of diseases associated with the TGF-b-signaling
pathway.Shprintzen-Goldberg syndrome (SGS [MIM 182212]) has
been described as being associated with intellectual
disability (ID), marfanoid habitus (including arachnodac-
tyly, pectus deformity, scoliosis, and pes planus with foot
deformity), camptodactyly, and facial dysmorphism
(including hypertelorism, exophthalmos, downslanting
palpebral fissures, and maxillary and mandibular hypo-
plasia). The hallmark of this syndrome, although inconsis-
tent, is the presence of craniosynostosis1,2 (see Web
Resources). Other findings include mitral valve prolapse,
recurrent hernias, loss of subcutaneous tissue, and thin
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not known whether individuals with SGS display an aortic
risk because some rare cases have been described with
aortic dilatation1,2 (see Web Resources). We assumed that
SGS is an autosomal-dominant disorder on the basis of
previous descriptions of simplex cases (although recur-
rence in siblings has been reported).3 Because of the clin-
ical overlap with Marfan syndrome (MFS [MIM 154700])
and Loeys-Dietz syndrome (LDS1A [MIM 609192], LDS1B
[MIM 610168], LDS2A [MIM 608967], LDS2B [MIM
610380], LDS3 [MIM 613795], and LDS4 [MIM 190220]),
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Figure 1. Clinical Presentations and Pedigrees of Subjects with SGS and Mutations in SKI
(A) Photographs of affected individual II-1 (from family 2), who has a SKI de novo c.94C>G variant. Note the hypertelorism, proptosis,
downslanting palpebral fissures, maxillary andmandibular hypoplasia, low-set ears (Aa–Ac), joint contractures (Ad), arachnodactyly and
camptodactyly (Ae), deformed feet (Af–Ag), severe scoliosis (Ah), translucent skin (Ai), and hypertrophy of the palatal shelves (Aj).
(B) Photographs of affected individual 14 (family 8), who has a SKI de novo c.103C>T variant. Note the dysmorphic features in favor of
SGS (Ba–Bb), severe pectus carinatum (Bc), arachnodactyly, and camptodactyly (Bd).
(C) Photographs of affected individual III-4 (from family 3), who has a c.280_291delTCCGACCGCTCC variant in exon 1 of SKI. Note the
dysmorphic features and habitus in favor of SGS (Ca, Cc, and Cd), foot deformity (Cb), and hand deformity with camptodactyly (Ce).
(D) Photographs of affected individual IV-2 from family 3 (child of individual III-4 in C).
(E) Pedigrees of families 1 (F1), 2 (F2), 3 (F3), and 4 (F4) studied by exome sequencing. Individuals studied are shown by an arrow.190181), and TGFBR2 (MIM 190182) should be excluded.4
We hypothesized that SGS is a clinically distinct entity
resulting from heterozygous mutations of other gene(s)
involved in the TGF-b-signaling pathway.
We recruited a cohort of 19 SGS-affected individuals
originating from six European countries and Australia.
The cohort included five related individuals from a family
consistent with autosomal-dominant inheritance (family
3), another family with recurrence in siblings (family 4)3
(Figure 1 and Table 1), ten simplex cases (including one
previously published individual),5 and one probable auto-
somal-dominant case. We also additionally assembled
a second cohort of 11 individuals with marfanoid habitus
and craniosynostosis; these individuals did not present
with the dysmorphic features of SGS (Table S1, available
online). Informed consent for research investigations was
obtained from the affected individuals, legal representa-The Americantives, or relatives. The research protocol was approved by
the local ethics committees. The 30 individuals were first
screened for FBN1, TGFBR1, and TGFBR2 mutations by
direct sequencing and multiplex ligation-dependent probe
amplification and for chromosomal rearrangements by
180K or 244K Agilent array comparative genomic hybrid-
ization. We identified simplex heterozygous missense
mutations in FBN1 (c.3761G>A [p.Cys1254Tyr]; RefSeq
accession number NM_000138.4), TGFBR1 (c.734A>G
[p.Glu245Gly]; RefSeq NM_004612.2) and TGFBR2
(c.1583G>A [p.Arg528His]; RefSeq NM_003242.5) in three
individuals from the second cohort (Table S1 and
Figure S1).
First, we used the Nimblegen SeqCap EZ Exome v.2.0 kit
to perform exome sequencing in two trios (families 1 and 2;
Figure 1) with simplex SGS according to standard proce-
dures; we used 8 mg of DNA from affected individualsJournal of Human Genetics 91, 950–957, November 2, 2012 951
Table 1. Detailed Clinical Features of SGS Individuals and Summary of the Detected Mutations in SKI
Family 1 Family 2 Family 3 Family 4 Family 5 Family 6 Family 7 Family 8 Family 9 Family 10 Family 11 Family 12 Family 13
TotalII-1 II-1 III-4 IV-2 II-1 III-1 III-2 II-2 II-3 II-4 11 12 13 14 15 16 17 18 19
Sex F F M F F F M F F F M M F F F F M M M 12F
and 7M
Age (years) 21 20 42 11 44a 13 14 22 22 20 18 16 5 21 10a 11 32 20 26 
Craniosynostosis þ þ      þ þ þ þ þ  þ þ þ  þ þ 12/19
Arachnodactyly  þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ 18/19
Pectus deformity þ þ þ     þ þ þ þ þ þ þ þ þ þ þ þ 15/19
Scoliosis  þ þ þ þ  þ þ þ þ þ þ  þ þ þ þ þ þ 16/19
Joint contractures þ þ þ þ þ þ þ þ þ þ  þ  þ þ þ  þ  15/19
Camptodactyly þ þ          þ  þ þ þ þ þ þ 9/19
Foot malposition þ þ þ þ þ þ þ þ þ þ þ þ  þ þ þ þ þ  17/19
Scaphocephaly or
dolichocephaly
þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ  þ þ þ 18/19
Hypertelorism þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ  þ þ þ 18/19
Proptosis þ þ þ  þ þ  þ þ  þ  þ þ þ þ þ þ þ 15/19
Downslanting
palpebral fissures
þ þ þ þ þ þ þ þ þ þ þ þ þ þ  þ þ   16/19
Micrognathia
or retrognathia
þ þ þ  þ   þ þ þ þ þ þ þ þ  þ þ þ 15/19
Intellectual disability þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ þ 19/19
Hernias        þ þ þ þ  þ þ þ þ þ þ þ 11/19
Loss of subcutaneous fat þ       þ þ   þ  þ þ   þ  7/19
Valvular anomalies           MVP   MVP MVP, MI MVP MVP, MI   5/19
Aortic root dilatation           þb    UNL þ þ   3/19
Myopia   þ þ þ þ  þ þ N/A     þ  þ   8/18
SKI mutation c.100
G>T
c.94
C>G
c.280_
291del
TCCG
ACCG
CTCC
c.280_
291del
TCCG
ACCG
CTCC
c.280_
291del
TCCG
ACCG
CTCC
c.280_
291del
TCCG
ACCG
CTCC
c.280_
291del
TCCG
ACCG
CTCC
c.101
G>T
c.101
G>T
c.101
G>T
c.104
C>A
c.94
C>G
c.283_
291del
GACC
GCTCC
c.103
C>T
c.95
T>C
c.100
G>A
c.94
C>G
c.92
C>T
 
Amino acid substitution p.Gly
34Cys
p.Leu
32Val
p.Ser
94_Ser
97del
p.Ser
94_Ser
97del
p.Ser
94_Ser
97del
p.Ser
94_Ser
97del
p.Ser
94_Ser
97del
p.Gly
34Val
p.Gly
34Val
p.Gly
34Val
p.Pro
35Gln
p.Leu
32Val
p.Asp
95_Ser
97del
p.Pro
35Ser
p.Leu
32Pro
p.Gly
34Ser
p.Leu
32Val
p.Ser
31Leu
 18/19
Inheritance de novo de novo AD AD AD AD AD AD, SM AD, SM AD, SM de novo father
N/A
de novo de novo de novo parents
N/A
parents
N/A
parents
N/A
AD 
The following abbreviations are used: AD, autosomal dominant; F, female; SM, somatic mosaicism; M, male; MVP, mitral valve prolapse; MI, mitral insufficiency; N/A, not available; and UNL, upper normal limit.
aAffected individual 5 died of respiratory insufficiency. Affected individual 15 died suddenly, and an autopsy showed severe mitral valve dysplasia with calcifications of the mitral annulus.
bAortic dilatation requiring surgery at 16 years of age (aortic root dilatation with Z score ¼ 7.014). He also has vertebrobasilar and internal carotid tortuosity and a dilated pulmonary-artery root.
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and both parents (Figure S1). The resulting exome-capture
libraries underwent two 75 bp paired-end sequencing runs
on an Illumina HiSeq 2000. Reads were aligned to the
human reference genome (GRCh37/hg19) with the
Burrows-Wheeler Aligner,6 and potential duplicate
paired-end reads were removed with Picard v.1.22 (see
Web Resources). The Genome Analysis Toolkit (GATK)
v.1.0.57 was used for base quality-score recalibration and
indel realignment,7 as well as for single-nucleotide-variant
and indel discovery and genotyping with the use of stan-
dard hard-filtering parameters.7 Variants with a quality
score < 30, allele balance > 0.75, sequencing depth < 4,
quality-to-depth ratio < 5.0, length of homopolymer
run > 5.0, and strand bias > –0.10 were flagged and
excluded from subsequent analyses. We used the GATK
Depth of Coverage tool to assess coverage by ignoring
reads with a mapping quality < 20 and by ignoring bases
with a base quality< 30. In total, 92% of the primary target
was covered at least four times in all individuals (Table S2).
All variants identified in the affected individuals were
annotated with SeattleSeq SNP annotation (see Web
Resources). We focused on de novo heterozygous exonic
variants (missense, nonsense, and splice-site variants and
coding indels). Candidate mutational events were then
inspected with the Integrative Genomics Viewer (see Web
Resources).8 The resulting variants were excluded when
the frequency was over 1/1,000 in the National Heart,
Lung, and Blood Institute (NHLBI) Exome Variant Server
(EVS) (see Web Resources). After applying variant calling
filters, we failed to identify any candidate de novo muta-
tions. Indeed, none of the variants identified in family 1
were confirmed by Sanger sequencing, and two de novo
variants were confirmed in family 2. The first de novo
variant was a COL4A4 (RefSeq NM_000092.4) missense
mutation (c.4423G>T [p.Asp1475Tyr]) that is likely to
cause benign hematuria only. The second de novo variant
was a C1ORF54 (RefSeq NM_024579.3) frameshift muta-
tion (c.272delT [p.Val91Glufs*3]). Because C1ORF54 is pre-
dicted to encode a brain-, smooth-muscle-, and skin-
secreted extracellular protein, the gene was sequenced in
the rest of the cohort, but no pathogenic mutation was
identified (conditions are available on request).
Subsequently, we performed exome sequencing by using
Nimblegen Exome v.3.0 capture in the two most distant
affected relatives (individuals III-1 and IV-2, who share
1/32 of their genomes) from family 3 and in one (indi-
vidual II-3) of the three affected siblings from family 4, as
well as in all of their unaffected parents (Figure 1), in accor-
dance with the manufacturer’s recommendations. After
mapping the raw sequencing reads against the reference
genome and applying the same variant calling filters, we
searched for heterozygous variants present in both distant
relatives in family 3 and for heterozygous variant calls
present in one sibling but absent in both parents in family
4 according to the gonadal-mosaicism hypothesis (Table
S2). We first identified 314 variants shared by the two
distant affected individuals from family 3. ConsideringThe Americanthe hypothesis of the implication of the TGF-b pathway,
we set up a biological filter with the EMBL-EBI reac-
tome,9 and 42 partners were listed (Table S3). When
we filtered against EVS data and the TGF-b-signaling bio-
logical filter, only SKI was revealed (Table S2). Indeed, we
found a 12 bp deletion (c.280_291delTCCGACCGCTCC
[p.Ser94_Ser97del]) in a highly conserved region of exon
1 of SKI (RefSeq NM_003036.3) (Figure 2). Remarkably, in
the first attempt of exome analysis, no SKI mutation
was detected in family 1 or 2, but we noted that exon 1
(and therefore the mutational hotspot) was not covered
by v.2.0 of Nimblegen SeqCap EZ Exome capture. By
reducing the quality filters and the number of reads in
family 4, we detected suggestive evidence of a missense
mutation (c.101G>T [p.Gly34Val]; two reads) in SKI
(RefSeq NM_003036.3). Sanger sequencing confirmed
this mutation and the segregation in favor of a somatic
mosaicism given that we found a lower level of the mutant
allele in the asymptomatic mother. We performed PCR
reactions on genomic DNA by using primers designed to
amplify all seven exons and intron-exon boundaries of
SKI in the remaining individuals from the SGS and non-
SGS marfanoid-craniosynostosis cohorts (Table S5). After
a variant was identified, the parents were secondarily
studied when available. It was difficult to set up PCR condi-
tions for the amplification of SKI as a result of GC-rich
regions, particularly in exon 1. Because of the size of
exon 1, it was necessary to design three pairs of primers
(E1-1, E1-2, and E1-3), and a new pair of primers was neces-
sary for achieving the sequencing of the hot-spot region
(named E1-ATG, Table S5). PCR fragments were purified
with themultiscreen VacuumManifold system (Millipore).
Sequencing was performed with the ABI BigDye Termi-
nator Cycle Sequencing kit (v.3.1) (Applied Biosystems)
in ABI 3130 sequencer 7 (Applied Biosystems) according
to the manufacturer’s instructions. Sequence data were
analyzed with SeqScape v.2.7 (Applied Biosystems). The
pathogenicity of missense mutations was tested with Poly-
Phen-2 and SIFT online software (see Web Resources).10
Screening of our entire cohort of SGS individuals revealed
a total of ten de novo missense mutations, including
somatic mosaicism in a family with recurrence in siblings
and two overlapping in-frame deletions (one of them
was dominantly inherited in a large family) (Table 1 and
Tables S4 and S5), accounting for 18 of 19 cases tested.
All mutations were found in the R-SMAD binding
domain, affecting five conserved residues. Familial segrega-
tion and in silico prediction models were in favor of their
pathogenicity (Table S4). A three-dimensional protein
modeling was realized with Phyre2 software (see Web
Resources). An automatic modeling script with standard
parameters in the Phyre2 pipeline was used for generating
the Protein Data Bank file of the protein. Overall, 83% of
residues were modeled at >90% confidence, and 104 resi-
dues were modeled ab initio. A detailed description of
the protein-modeling results is provided in Figure 3. We
also sequenced SKI in the second cohort of individualsJournal of Human Genetics 91, 950–957, November 2, 2012 953
Figure 2. Location of SGS-Associated Mutations in SKI
(A) Schematic representation of the seven coding exons of SKI (top). The 50 and 30 UTRs are denoted in light gray. Exon 1 encodes the
N-terminal R-SMAD- and SMAD- binding domains (blue and red box, respectively, at the bottom) and the DHD domain (purple box),
and the remaining exons encode the C terminus with its two coiled-coil domains (green boxes at the bottom). Sites for interaction with
N-CoR andmSin3 are also shown as light blue and dark blue lines, respectively. All mutations (asterisks formissense variants and lines for
deletions) are located in the R-SMAD binding domain.
(B) Highly conserved amino acid residues (indicated in dark boxes) are conserved in vertebrates. All mutations affect highly conserved
residues. The following abbreviations are used: Hs, Homo sapiens; Ms, Mus musculus; Cf, Canis familiaris; Bt, Bos Taurus; Mac, Macropus
eugeneii; Gg, Gorilla gorilla; and Dr, Danio rerio.with a marfanoid-craniosynostosis phenotype incompat-
ible with SGS but found no variant, thus further high-
lighting the phenotypic and genetic specificity of SGS.
Here, we report the identification of heterozygous exon
1 SKImutations in 18 cases presenting with the character-
istic features of SGS. The identification of recurrent hetero-
zygous mutations in a specific area of exon 1 will facilitate
genetic screening and help genetic counseling. Our results
also feature information useful in clinical care because
three individuals of the SGS cohort presented with aortic
dilation; one such individual had vertebrobasilar and
internal carotid tortuosity and a dilated pulmonary-artery
root, further highlighting the overlap between SGS and
Loeys-Dietz syndrome (Table 1).11 Therefore, a transtho-
racic echocardiogram, as well as imaging by computed
tomography or magnetic resonance imaging of the neck,
thorax, abdomen, and pelvis, can be justified. All of the
individuals with SKI mutations had intellectual disability,
supporting the hypothesis that SGS and Furlong syndrome954 The American Journal of Human Genetics 91, 950–957, Novembshould be separate.12 Given the absence of SKI mutation
from the second cohort with non-SGS marfanoid craniosy-
nostosis, we can conclude that other gene(s) remain to be
determined for other types of marfanoid-craniosynostosis
syndromes.
Several lines of evidence implicate the TGF-b pathway in
marfanoid habitus, and SGS-affected individuals present
with severe marfanoid habitus, allowing us to apply a
biological filter strategy to select variants in the TFG-b
pathway.9 SKI is an outstanding candidate gene because
it encodes a ubiquitous transcription factor with a precise
pattern of spatiotemporal constitutional expression and
is implicated in promoting differentiation and maturation
of chondrocyte cells and inhibiting proliferation of cells.
SKI is implicated in the repression of TGF-b signaling,
mainly through inhibition of SMAD2 phosphorylation,
and competes with pSMAD3-SMAD4 binding and recruit-
ing transcriptional repressor proteins such as N-CoR and
mSIN3 (Figures 2 and 3 and Figure S2).13–16 Mutationser 2, 2012
Figure 3. Three-Dimensional Modeling of SKI
(A) Functional domains of wild-type protein composed of an N-terminal DNA transcriptional regulating domain (dark blue) including
R-SMAD (light blue) and DHD domains, a central SMAD4-interacting domain (greenish yellow), and a C-terminal coiled-coil
domain (red).
(B) Enlargement of the region affected by all the mutations. The in-frame deletions shorten a loop (between residues 92 and 97). The
missensemutations disrupt a flexible region (residues 31–35). All themutations are localized on the same surface of the R-SMAD-binding
domain.found in the reported individuals affect the SMADs inter-
acting domain and the transcription regulation domain
DHD. All the mutated residues induce polarity changes
and are located on the same structural surface, suggesting
modification of the binding properties of SKI to the
SMADs. The identified mutations in the SMAD interacting
domains could lead to abnormal transcriptional repression
of the downstream TFG-b signaling.16 Furthermore, Ski/
mice display a lethal phenotype with associated midline
facial cleft, a depressed nasal bridge, eye anomalies, skeletal
muscle defects, and digital anomalies.17 Besides the mouse
knockout model, the other major argument linking the
SGS phenotype with SKI mutations is the role of SKI in
the TGF-b pathway, a role which has been implicated in
marfanoid habitus. It has been shown that the regulation
of TGF-b signaling by SKI plays an important role in chon-
drocyte differentiation and maturation.18 Because the
SMAD4-SKI complex modulates the transcription of genes
regulated by TGF-b signaling, missense mutations within
SMAD-interacting domains could lead to abnormal tran-
scriptional repression of the downstream TGF-b-signaling
genes in SGS (Figure 2 and Figure S2).
Interestingly, the hallmark of most diseases with defects
in the TGF-b pathway is the high risk of developing
thoracic aortic aneurysms (TAAs), although aortic compli-
cations seem less frequent in the SGS cohort.1 However,
this finding could be explained by the young age of the re-
ported individuals. Recently, functional studies in SMAD3The Americanmutants raised the hypothesis that the ERK noncanonical
TGF-b pathway could be implicated in TAAs. A crucial
pathophysiologic distinction between canonical and non-
canonical pathway activation points to the importance
of the chronic activation of the noncanonical TGF-b
pathway in the development of vascular symptoms inmar-
fanoid syndromes.19 In Myhre syndrome (MIM 139210),
SMAD4mutations in the mad homology 2 domain protect
mutant SMAD4 complexes from ubiquitination and
impair the expression of TGF-b-driven target genes.20,21
Accordingly, the increased accumulation of SMAD4 in
Myhre syndrome results in developmental delay and short
stature and has no known risk of TAAs.21 Further studies
would be useful for better understanding this aspect of
the disease.
Myhre syndrome and SGS are the only TGF-b-pathway-
related syndromes associated with ID. This feature can be
explained in SGS given that SKI is necessary for neuronal
proliferation and maturation and has been designated as
a critical gene for ID in 1p36 telomeric deletion. Indeed,
expression of SKI has been reported to be regulated
by axon-Schwann-cell interactions and to be a crucial
signal in Schwann cell development and myelination.22
The SKI/SnoN domain of Drosophila melanogaster and
Caenorhabditis elegans was shown to be necessary for the
proper cellular differentiation of neuronal progenitors.23
Moreover, Baranek et al. also showed that SKI, as a repressor
of the TGF-b pathway, modulates its action during corticalJournal of Human Genetics 91, 950–957, November 2, 2012 955
development through recruitment of the Sin3/HDAC
complex to SMADs and thereby fine tunes the balance
between proliferation and differentiation of progenitor
cells.24
In conclusion, our findings show that in-frame muta-
tions in exon 1 of SKI cause SGS. Additional studies are
necessary for elucidating the region-specific and tissue-
specific consequences of defective SKI-mediated TGF-b
signaling. Furthermore, because SKI mutations could not
be identified in a cohort with non-SGS marfanoid cranio-
synotosis, mutations in yet-to-be-identified genes are
most likely responsible for other types of marfanoid-cra-
niosynostosis syndromes.Supplemental Data
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